pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

Discontinuation rates, severe adverse events (SAE), and adverse events (AE) in the three clinical trials

Discontinuation rate (%)SAE incidence (%)AE incidence (%)



E 140 mg (n = 507)E 70 mg (n = 787)pbo (n = 890)E 140 mg (n = 507)E 70 mg (n = 787)pbo (n = 890)E 140 mg (n = 507)E 70 mg (n = 787)pbo (n = 890)
‚ÄÉTotal1.761.531.221.572.121.9752.3550.7852.70

STUDY 1 (STRIVE)2.22.22.51.92.52.255.557.363.0
STUDY 2 (ARISE)-1.80.3-1.11.7-48.154.7
STUDY 3 (Tepper et al.)10.0<1 (approx 0.7)132474439

AE: adverse events; E: erenumab; pbo: placebo; SAE: severe adverse events

Korean J Clin Pharm 2019;29:71-8 https://doi.org/10.24304/kjcp.2019.29.2.71
© 2019 Korean J Clin Pharm